Yohe, M. E., Heske, C. M., Stewart, E., Adamson, P. C., Ahmed, N., Antonescu, C. R., Chen, E., Collins, N., Ehrlich, A., Galindo, R. L., Gryder, B. E., Hahn, H., Hammond, S., Hatley, M. E., Hawkins, D. S., Hayes, M. N., Hayes-Jordan, A., Helman, L. J., Hettmer, S., Ignatius, M. S., Keller, C., Khan, J., Kirsch, D. G., Linardic, C. M., Lupo, P. J., Rota, R., Shern, J. F., Shipley, J., Sindiri, S., Tapscott, S. J., Vakoc, C. R., Wexler, L. H., Langenau, D. M. (June 2019) Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatr Blood Cancer, 66 (10). article no. e27869. ISSN 1545-5009
Abstract
Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.
| Item Type: | Paper |
|---|---|
| Subjects: | diseases & disorders > cancer diseases & disorders diseases & disorders > cancer > drugs and therapies > chemotherapy diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Vakoc lab |
| Depositing User: | Matthew Dunn |
| Date: | 21 June 2019 |
| Date Deposited: | 08 Aug 2019 14:06 |
| Last Modified: | 05 Feb 2024 21:09 |
| PMCID: | PMC6707829 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/38141 |
Actions (login required)
 |
Administrator's edit/view item |